Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rPhleum Immunotherapy Dose-Response Study
NCT00666341Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Sep 2007
- Primary completion
- Jan 2009
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of rPhleum in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by Allergopharma. Started Sep 2007; status: completed.
02
Drugs
rPhleum
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00666341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666341.